LexaGene to Present at Lytham Partners Virtual Investor Growth Conference
BEVERLY, Mass. – June 22, 2020 – LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection, is scheduled to participate in a virtual presentation and fireside chat at the Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 1:00pm ET (10:00am PT).
A webcast of the presentation will be posted under the investor relations section of LexaGene’s website at www.lexagene.com, or can be accessed at https://www.webcaster4.com/Webcast/Page/2419/35342 or www.lythampartners.com/virtual. A replay of the presentation will be available following the event.
Management will also be participating in virtual one-on-one meetings on June 24 and 25, 2020. To arrange a meeting, please contact Joe Dorame of Lytham Partners at email@example.com or visit www.lythampartners.com/virtual.
To be added to the LexaGene email list, please subscribe on the Company website.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Director
About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.